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p66Shc, a member of the ShcA (Src homologous- collagen homologue) adaptor protein family, is one of the three
isoforms of this family along with p46Shc and p52Shc. p66Shc, a 66 kDa protein is different from the other isoforms
of the ShcA family. p66Shc is the longest isoform of the ShcA family. p66Shc has an additional CH domain at the
N-terminal, called the CH2 domain, which is not not present in the other isoforms. This CH2 domain contains a very
crucial S36 residue which is phosphorylated in response to oxidative stress and plays a role in apoptosis. Whereas
p52Shc and p46Shc are ubiquitously expressed, p66Shc shows constrained expression. This adaptor protein has
been shown to be involved in mediating and executing the post effects of oxidative stress and increasing body of
evidence is pinpointing to its role in carcinogenesis as well. It shows proto-oncogenic as well as pro-apoptotic
properties. This multitasking protein is involved in regulating different networks of cell signaling. On one hand it
shows an increased expression profile in different cancers, has a positive role in cell proliferation and migration,
whereas on the other hand it promotes apoptosis under oxidative stress conditions by acting as a sensor of ROS
(Reactive Oxygen Species). This paradoxical role of p66Shc could be attributed to its involvement in ROS
production, as ROS is known to both induce cell proliferation as well as apoptosis. p66Shc by regulating intracellular
ROS levels plays a crucial role in regulating longevity and cell senescence. These multi-faceted properties of p66Shc
make it a perfect candidate protein for further studies in various cancers and aging related diseases. p66Shc can be
targeted in terms of it being used as a possible therapeutic target in various diseases. This review focuses on p66Shc
and highlights its role in promoting apoptosis via different cell signaling networks, its role in cell proliferation, along with
its presence and role in different forms of cancers.
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The Shc family of proteins consists four members ShcA,
ShcB, ShcC and ShcD, of which the best characterized to
date is ShcA [1,2]. ShcA, or simply Shc, was identified in
1992 as an adaptor protein which linked the activated
EGFR (Epidermal Growth Factor receptor) to Ras and
the MAP (Mitogen Activated Protein) kinase cascade [3,4].
Shc is expressed as three isoforms which have the molecu-
lar weight of 66, 52 and 46 kDa respectively. These iso-
forms are designated according to their molecular weight.* Correspondence: khandayf@kfupm.edu.sa
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unless otherwise stated.All three of these isoforms are encoded by the same
genetic locus, although the lower molecular weight iso-
forms have alternate start sites resulting in different
amino-terminal sequences [5]. Expression of 52/p46Shc
and p66Shc is controlled by different promoters [6,7].
All three isoforms of the Shc family consist of the N-
terminal phosphotyrosine-binding domain (PTB), the
middle collagen homology domain (CH1), and the C-
terminal Src-homology domain (SH2). p52Shc and
p66Shc have overlapping N-terminal sequences of 46
and 110 amino acids, respectively, which distinguishes
these isoforms from p46. These two isoforms have the
cytochrome c binding domain (CB), which is not
present in p46Shc. p66Shc is the longest isoform ofis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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domain (CH2), which is unique to it [8,6].
Role of Shc isoforms in the propagation of mitogenic
signals
p46Shc and p52Shc are ubiquitously expressed, while
p66Shc is expressed at different level in various tissues.
The CH1 domain of p46/p52Shc has three tyrosine resi-
dues which are phosphorylated in response to a number
of cell surface ligand activated receptors. p52Shc binds
to phosphorylated receptors via the PTB domain or the
SH2 domains in response to growth factors, and is phos-
phorylated on these tyrosine residues (Y239/240, Y317)
within the CH1 regions. Grb2 (Growth Factor Receptor-
bound Protein 2) forms a complex with SOS (Son of
Sevenless) protein. The Grb2/Sos complex is recruited by
the phosphorylated p52/p46Shc proteins. This Grb2/Sos
complex is then docked onto these phosphotyrosine resi-
dues, via direct interaction with the Grb2-SH2 domain,
which ultimately leads to the activation of Ras proteins
[1,7-10]. This coupling is implicated in the cytoplasmic
propagation of mitogenic signals. p66Shc, upon stimulation
by growth factors, is tyrosine phosphorylated by receptor
tyrosine kinases. p66Shc upon tyrosine phosphorylation
binds Grb2, and is unable to activate the Ras-MAPK-Fos
pathways [6,11]. Ras signaling pathway is also inhibited
when p66Shc is over-expressed upon stimulation by
growth factors or cytokines [11-13]. Stimulation of MEK
(MAPK-ERK Kinase)/ERK (Extracellular-signal Regulated
Kinase) pathway by Insulin Growth Factor (IGF-1) is also
inhibited by p66Shc. This pathway is required by the actin
cytoskeleton phosphorylation in skeleton muscle myo-
blasts [14].
Another adaptor protein E3b1 together with Eps8 also
plays a role in regulating the phosphorylation, reducing
ubiquitilation and increasing the stability of p66Shc pro-
tein through Rac1 [15]. Sos1 can exist in a complex with
Eps8/E3b1 and the complex of Sos1/Eps8/E3b1 leads to
the activation of Rac1 [15]. p66Shc plays the role of a
switch to dissociate Sos1 from the Grb2/Sos1 pool to
Eps8/E3b1 pool. This in turn leads to Rac1 activation
and as a result leads to an increase in the generation of
oxidants [10-12,16]. Increased binding of p66Shc to acti-
vated EGFR and Grb2 occurs during severe oxidative
stress. This binding leads to the dissociation of the Sos1
adaptor protein from the EGFR recruited signaling com-
plex. These events lead to the termination of the Ras/
MEK/ERK activation [17].
Interplay of p66Shc and ROS – implications in aging and
diseases
p66Shc is also a part of a signal transduction pathway
that is activated by increased intracellular ROS, leading
to apoptosis. The oxidative stress resistance and lifespanof a cell and an organism is increased by mutation of
this pathway. The accumulation of oxidatively damaged
macromolecules occurs in virtually all aging mammals
[18]. In C. elegans and Drosophila, it has been seen that
the genes controlling ROS metabolism play a role in deter-
mining lifespan. The decreased ROS production may be
responsible for increased lifespan [19,20]. ROS and p66Shc
have also been implicated in many diseases. Insulin has
been seen to activate the redox enzyme activity of p66Shc
specifically in adipocytes and p66Shc-generated ROS regu-
lates insulin signaling. Deletion of p66Shc in vivo has been
observed to increase metabolic rate as well as decrease fat
mass and resistance to diet-induced obesity. p66Shc gener-
ated ROS regulates the effect of insulin and may lead to
acceleration of aging by favoring fat deposition and as a re-
sult fat related disorders [21].
Furthermore, depletion of p66Shchas been shown to
lead to Warburg effect, causing enhanced glycolysis and
increased allocation of glucose-derived carbon into ana-
bolic metabolism. This role of p66Shc has been ob-
served in mice that are deficient in p66Shc. These
p66Shc deficient mice show resistance to diabetes and
obesity. This altered metabolism was seen to be medi-
ated by mTOR (mammalian target of rapamycin). This
indicates towards an inhibitory role of p66Shc in ana-
bolic metabolism, unlike other isoforms of Shc [22].
Stimulation of p66Shc expression by hypercholesterol-
emia was observed in platelets. This lead to increased
ROS levels in platelets in addition to hyperactivity and
hyper aggregation in hypercholesterolemia. These effects
were mitigated by down regulation of p66Shc [23]. p66Shc
levels were also seen to increase progressively in failing
myocytes that were affected by pacing-induced dilated car-
diomyopathy. Pacing-induced dilated cardiomyopathy is
characterized by an increased production of ROS and
apoptosis. p66Shc, however, was undetectable in case of
healthy cardiomyocytes [24]. p66Shc, therefore, plays a key
role in cardiovascular diseases and obesity by regulating
intracellular redox balance and oxidative stress levels [25].
p66Shc has also been shown to contribute to EAE (ex-
perimental autoimmune encephalomyelitis) induced neur-
onal damage. It does so, most likely, through the opening
of PT pore that triggers mitochondrial swelling and leads
to neurodegenerative stress [26]. In β-amyloid-mediated
cell toxicity, MKK6-p66Shc form an important signaling
cascade, wherein β-amyloid leads to apoptotic cell death
via phosphorylation on S36 residue of p66Shc. Here the
phosphorylation is carried out by MKK6 [27]. β-Amyloid
plays a role in Alzheimer’s disease and causes the gener-
ation of ROS [28] (Figure 1).
p66Shc phosphorylations – causes and consequences
p66Shc has a unique CH2 region at the NH2 terminal.
This CH2 region is of around 110 amino acids and, like
Figure 1 Multi-faceted properties of p66Shc – different stimuli and different responses.
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The CH2 region contains the unique and all important
serine phosphorylation (S36 and S54) sites [11]. p66Shc
also has a cytochrome C binding (CB) region between
the CH2-PTB domains. This is primarily involved in the
regulation of oxidative stress in the mitochondria [29].
The CH2 domain, which is unique for p66Shc, may
cause the selective regulation of translation of p66Shc
protein. In addition to this, the utilization of two alter-
nate promoters at the Shc locus may also play a role in
the constrained expression of p66Shc, as opposed to the
ubiquitous expression of p52Shc and p46Shc [30]. The ex-
pression of p66Shc is missing in peripheral blood lympho-
cytes, hematopoietic cell lines and neurons, its expression
varies in breast and prostate cancer cell lines, whereas, it is
primarily expressed in epithelial cells [5,11,31-34].
Under oxidative stress the S36 residue of p66Shc is
phosphorylated. Treatment with an iron-containing por-
phyrin, hemin increased the phosphorylation of p66Shc
at the S36 residue. In hemin treated K562 erythroleuke-
mic cells p66Shc was transcriptionally activated through
the ARE (Antioxidant response element)-Nrf2 (NF-E2-Re-
lated Factor 2) pathway [35]. In human colon carcinoma
cell line RKO and in diploid human dermal fibroblasts
suppression in the production of ROS was seen in shRNA-
mediated knockdown of p66Shc and an increase in the
production of ROS was observed upon overexpression of a
recombinant p66Shc. These effects were not seen in the
electron transport chain deficient ρ0-RKO cells. These ρ0-
RKO cells are mitochondrial DNA depleted cells [36].
Till now most of the studies have demonstrated that
p66Shc shows a pro-apoptotic and pro-oxidative role.
Up to 30% extension in lifespan was seen in p66Shcknockdown mice. These knockdown mice also showed
better handling of ROS and oxidative stress [6]. Muta-
genesis of S36 to alanine results in a p66Shc variant
that is unable to induce apoptosis. Therefore, S36 appears
to be a critical regulatory site for the apoptotic activity
and oxidative stress response of p66Shc [30,33,36-38].
This phosphorylation of the S36 residue of p66Shc in re-
sponse to oxidative stress is done by PKCβ, which is acti-
vated by oxidative stress [39]. Oxidative stress gives a
stimulus to mouse thymocytes, peripheral blood lympho-
cytes and splenic T-cells and these cells then attain the
ability to express p66Shc [12]. Phosphorylation of
p66Shc on the S36 residue has been shown to have a
pro-apoptotic effect in different cell lines. The re-
sponses of S36 phosphorylation depends on the kinase(s)
that mediate this process. The kinase(s) may differ
(MAPK, stress-activate JNK and P38) depending on
the cell type or the type of inducement [40-43]. When
faced with oxidative stress conditions, S36 on p66Shc
is phosphorylated which leads to the activation of
p66Shc [44] (Figure 2). This activated p66Shc sensitizes
to apoptotic stimuli after it is dissociated from an
inhibitory complex [45]. Apoptotic death induced by
oxidative stress is dependent on p53 and knockout of
either p53 or p66Shc leads to resistance. This suggests
that p66Shc is downstream of p53 in the pathway
leading from ROS to apoptosis [46].
The S54 site in the CH2 domain of p66Shc is important
for its stability [16]. The proteolytic PEST signal sequence
of p66Shc is disguised by the phosphorylation of S54 in
the CH2 domain and the T386 in the CH1 domain of
p66Shc. These phophorylations are mediated by Rac1, and
these Rac1 mediated phosphorylations lead to increase in
Figure 2 Triggers and responses of phosphorylation of p66Shc residues.
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it was also seen that p66Shc leads to the activation of Rac1
through the mediation of exchange factor Sos1 [10-12,16].
Recently it was seen that in SH-SY5Y cells or in the
mice cortex, exogenous H2S inhibited the mitochon-
drial ROS production and as a result, phosphorylation
of p66Shc and lead to sulfhydration of p66Shc on C59
residue [48]. ROS are known to regulate canonical Wnt
signaling. The canonical Wnt ligand, Wnt3a also in-
duces phosphorylation of p66Shc in endothelial cells.
The knockdown of p66Shc inhibited both β-catenin de-
phosphorylation that is stimulated by Wnt3a as well as
β-catenin dependent transcription. This inhibition was
seen to be reversed by the overexpression of p66Shc,
independent of Wnt3a. β-catenin dephosphorylation
brought about by exogenous H2O2 was also seen to be
mediated by p66Shc [49]. Many stimuli that are en-
gaged in tyrosine phosphorylation of p66Shc also bring
about the phosphorylation of S138 in the PTB domain
[37]. The association of p66Shc adaptor protein in tyro-
sine phosphorylation signaling pathway is well known.
Shc adaptor proteins, primarily p66Shc, transmit acti-
vated tyrosine phosphorylation signaling, which points
to their possible role in growth regulation including
carcinogenesis and metastasis [50].
p66Shc and apoptosis
The increased levels of ROS act as the trigger to inter-
fere with many cellular processes. These triggers result
in inhibition of cell proliferation and induction of apop-
tosis. Apoptosis is the process of programmed cell death
that takes place in multicellular organisms and com-
prises of many cellular events like cellular blebbing, nu-
clear fragmentation, chromosomal DNA fragmentation
and ultimately cell death. p66Shc is known to have a role
in apoptosis triggered by oxidative stress. The affirm-
ation to this has been seen in a number of studies. Oxi-
dative stress gives a stimulus to mouse thymocytes,peripheral blood lymphocytes and splenic T-cells and
these cells then attain the ability to express p66Shc
[40,45-48,50,51]. p66Shc overexpression lead to in-
creased stress induced apoptosis [6]. p66Shc-/- cells
are unable to restore pro-apoptotic responses when ex-
posed to H2O2. All these studies point to the fact that
p66Shc is needed for bringing about apoptosis. Phos-
phorylation of p66Shc on the S36 residue has been
shown to have a pro-apoptotic effect in different cell
lines. Upon expression of p66S36A mutant into these
p66Shc-/- cells, they are still not able to restore the
pro-apoptotic responses [6,28-30].
The gene encoding p66Shc has also attracted major
interest in aging research in the recent years since it
plays a vital role in apoptosis induced by oxidative stress.
p66Shc is known to have a crucial role in the regulation
of intracellular ROS levels [46]. The accumulation of
oxidatively damaged macromolecules occurs in all aging
mammals [18]. Activity of the mammalian forkhead
homolog, FKHRL1, was seen to be increased and the
redox dependent forkhead inactivation was seen to be
reduced in p66Shc-/- cells. In addition to this, an in-
crease in hydrogen peroxide scavenging as well as oxi-
dative stress resistance was observed upon expression of
FKHRL1. This points to a functional relation between
forkhead protein, p66Shc and ROS, the three regulators
of aging [52].
ROS can either originate from exogenous sources such
as ultraviolet and ionizing radiations, or it can be en-
dogenous (mitochondrial and certain enzymes). ROS has
been implicated in the damage of cellular proteins, lipids
and DNA. This oxidative cellular damage is apparently
the main origin of aging. It causes mutations and dele-
tions in both nuclear as well as mitochondrial DNA
[18,44,53]. Various studies have revealed the association
of cellular senescence and oxidative stress up-regulation
of ROS in humans, with the increased expression of
p66Shc [54-56]. The mitochondria contributes to the
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from the electron transport chain [57]. p66Shc has emerged
as a part of this mitochondrial ROS production. ROS pro-
duction in mitochondria is regulated by many factors such
as mitochondrial membrane potential, substrate supply and
the level of metabolic activity. The mitochondrial pool of
p66Shc forms a complex with Hsp70. Hsp70 is a chaper-
onin protein that is involved in protection from oxidative
stress induced mitochondrial damage. When stimulated by
UV radiation, this complex is released, pointing toward the
role of Hsp70 in inhibiting the apoptogenic property of
p66Shc [45]. In response to oxidative stress, part of the
cytosolic pool of p66Shc is translocated to the mitochon-
dria, which already has as high as 20 percent of fibroblast
p66Shc localized in it [45]. p66Shc acts as an oxidoreduc-
tase in the mitochondria. After binding to cytochrome C,
p66Shc shuttles electrons from cytochrome C to molecular
oxygen [29]. This redox activity of p66Shc leads to the in-
crease in ROS production caused by the recombinant ex-
pression of p66Shc. This explains the decrease in ROS
levels typical of p66Shc knockout cells [58]. MEFs (Mouse
embryo fibroblasts) from p66Shc-/- transgenics were found
to be resistant to apoptotic death that is induced by oxida-
tive stress. Furthermore, it has been demonstrated that the
cells derived from p66Shc-/- mice show a decrease in the
oxidation of the C8 of guanine, as well as, in the mutation
of mitochondrial DNA [59].
The p66Shc-/- fibroblasts cells have altered bio-
energetic properties vis-à-vis decreased resting and max-
imal oxidative capacity. This suggests that deletion of
p66Shc may extend lifespan by shifting metabolic energy
away from oxidative and toward glycolytic pathway [60].
One can, therefore, interpret that p66Shc mediates trig-
gering of apoptosis [61], and its deletion leads to a sig-
nificant increase in lifespan. It is apparent that the main
reason for the prolonged lifespan of p66Shc-/- mice is
the decreased intracellular ROS levels. The survival and
reproduction of p66Shc-/- mice in a population living in
an outdoor enclosure for a year was studied. It was ob-
served that p66Shc-/- mice had defects in fat accumula-
tion, thermoregulation as well as reproduction, pointing
to the role of p66Shc in energy metabolism and to the
difference in the results in protected laboratory condi-
tions and natural conditions [62].
p66Shc and crosstalk with p53
The tumor suppressor p53 is critically involved in oxidative
stress-dependent apoptosis. p53 has a role in mediating
the oxidative stress response of p66Shc, since p53 is up-
regulated upon treatment with H2O2 and UV. p53-/- MEFs
also show resistance to UV-induced and H2O2-induced
apoptosis [6]. It has been demonstrated that p66Shc serves
as a downstream effector of p53 [46]. Increased expression
of p53 in DLD-1 colon cancer cells and WT MEFs, lead toa significant increase of p66Shc [46]. p66Shc is not in-
volved in functions of p53 such as cell cycle arrest but
p66Shc does regulate the p53-dependent apoptosis [46]
(Figure 3). Activation of p53 leads to an increase in the
ROS levels via the release of cytochrome C from the mito-
chondria and the apoptosome assembly. p66Shc-/- cells
failed to increase the ROS levels upon increasing the ex-
pression of p53 because they were unable to trigger cyto-
chrome C release. The levels of ROS were increased in
these after the expression of p66Shc in p66Shc-/- MEFs,
pointing to the crucial role of p66Shc and p53 in the regu-
lation of intracellular ROS levels [46].
p66Shc and regulation of anoikis
The most important property of multicellularity is that
cells can grow and differentiate only when in the correct
context within a tissue, and can remove themselves by
apoptosis when they are not. Specific interactions with
the ECM (extracellular matrix) help the cells to sense
their location as well as that of the neighboring cells.
When these cell-ECM interactions are incorrect, apop-
tosis takes place. This kind of location specific apoptosis
is termed anoikis. Anoikis is a special case of pro-
grammed cell death that is initiated by cell detachment
instead of the normal pro-apoptotic signals [63]. Anoikis
is an essential mechanism for making sure that cells
maintain their proper positioning and avoid colonization
of distant organs. Aniokis resistance is a vital step of cancer
progression and metastatic colonization. Cancer cells de-
velop anoikis resistance by a variety of mechanisms such
as the over activation of receptors, modulating matrix stiff-
ness, increasing oxidative stress etc. [64].
Cells that lack p66Shc have been shown to escape
anoikis. Anoikis in these cells was restored with the
reexpression of p66Shc. p66Shc restores anoikis via
RhoA activation. Transient as well as stable transfec-
tions with p66Shc lead to cell death in detached cells,
but not in adherent cells. In contrast to apoptosis
caused by oxidative stress, this ability of p66Shc to
confer anoikis properties is not dependent on S36
phosphorylation of p66Shc [65]. In addition to this, it
was also seen that in the absence of p66Shc native K-
Ras behaves like oncogenic Ras. Ras was activated in
the absence of p66Shc in normal as well as malignant
cells. This hyperactivated Ras lead to the inhibition of
anoikis rather than leading to increased proliferation
rates. The metastatic effect in these cells was lost upon
re-expression of p66Shc [66]. Thus p66Shc functions
as a regulator of anoikis and has a role in the preven-
tion of metastasis.
p66Shc and cell proliferation
Cell proliferation, migration and adhesion are the main
properties of a tumor cell. Tumor cells proliferate, migrate
Figure 3 Schematic representation of the possible role of p53 in the p66Shc mediated oxidative stress induced apoptosis.
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cell to obtain metastatic phenotype. Cell proliferation and
migration depend on the signals transmitted by growth
factors and adhesion proteins [67]. These processes are
mainly regulated by the Rho family proteins and ERK cas-
cades [19,67-69]. Shc binding has been shown to be
needed in cell motility induced by the nerve growth factor
receptor trkA [70]. The processes of migration, prolifera-
tion and adhesion require the rearrangement of actin cyto-
skeleton. It involves the release of pre-existing cell-matrix
contacts and formation of new integrin substratum con-
tacts [71]. p66Shc mediates cell proliferation mediated by
growth factor receptor signaling, and also plays a crucial
role in cell migration and adhesion [72,73].
p66Shc also plays a crucial role in proliferation of epi-
thelial cells. The processes of cell proliferation and apop-
tosis have to be well balanced. The balance of these two
processes is governed by signal transduction machinery
[74]. Any imbalance between these two processes can
cause various life threatening diseases like autoimmune
diseases, cancer etc. [75-77]. The Shc proteins are one of
the most extensively studied adaptor proteins for under-
standing the role of adaptor proteins in cell signaling
pathways. As a result the role of Shc proteins in various sig-
naling pathways has received much attention [11,30,78-80].
Steroid hormones play a role in regulating the expression
of the Shc proteins [50]. Steroid hormones also play a role
in various cancers and regulate processes like cancer cell
proliferation and progression [81]. The excess of steroids in
hormone related cancers causes aberrant growth regulation
due to elevated levels of various growth factors [82-84]. In
addition to this, well established connections between
steroid hormones and tyrosine phosphorylation signal-
ing are already present [70,82,84-89]. Carcinogenesis is,
in turn, mainly regulated by growth factors and their re-
ceptors. These regulate processes like cell proliferation,motility, migration, invasion etc. [4,5,46,70,90-95]. It is
quite evident that Shc proteins play a role in carcino-
genesis. Aberrant expression of p66Shc has been seen
to be involved in carcinogenesis [8,31,79,80,96-98].
p66Shc in breast cancer
ARF1 has been found in complex with Grb2 and p66Shc
upon EGF stimulation of the basal like breast cancer MDA-
MB-231 cell line. The small GTPases ARF1 and ARF6 have
been shown to be activated downstream of the EGFR and
act as key regulator of growth, migration and invasion of
breast cancer cells [99]. Estrogen treated breast cancer
MCF-7 cells also showed an increase in both p66Shc pro-
tein level as well as the cell growth [79]. The metastatic
variant of breast cancer MDA-MB-231 cell line F-11 cells
have a 3-fold higher level of p66Shc expression as com-
pared to MDA-MB-231 cells, whereas the levels of p46 and
p52 isoforms remained unchanged [31]. The levels of
p66Shc were measured in primary breast cancer specimens.
The breast cancer specimens that were associated with
lymph node metastases, showed an increase in the level of
p66Shc. Higher levels of p66Shc correlate with higher
metastatic potential in breast cancer [31]. Decrease in ShcA
levels or conversely the expression of a dominant-negative
ShcA mutant lead to the blocking of motility induced by
TGF-β and furthermore also leads to the inhibition of inva-
sion of Neu/ErbB2- expressing breast cancer cells [13].
p66Shc forms a trimeric complex with alpha-1-syntrophin
and Grb2. The formation of this complex triggers cell pro-
liferation and migration of MCF-7 and HBL-100 breast
cancer cell lines. The role of p66Shc in cell proliferation
was analyzed in these cells by knock-down approach, where
siRNA against p66Shc was used. A marked decrease in cell
proliferation was observed by this method, pointing to the
role and importance of p66Shc in cell proliferation in breast
cancer cell lines [100].
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p66Shc protein levels were seen to be closely correlated to
the growth rate of prostate cancer cells. p66Shc protein
levels were also seen to be significantly higher in prostate
cancer adenocarcinomas as compared to the adjacent be-
nign glandular cells [79,97]. p66Shc protein level was seen
to be 4–10 times higher in rapidly growing prostate cancer
cells such as PC-3 and DU145 cells, as compared to slow
growing cells such as LNCaP C-33 [101]. The p66Shcpro-
tein level as well as the cell proliferation rate is increased in
these slow growing human prostate cancer cells when they
are treated with androgen or EGF. These levels are higher
than the corresponding cells grown without the stimulus
[79]. The role played by p66Shc protein in regulating the
growth of prostate cancer cells has been supported by both
cDNA as well as siRNA approaches [101]. Cell proliferation
was observed when the expression of p66Shc was increased
by cDNA transfections. Knock-down of p66Shc by its
siRNA decreased cell growth rate. Decreased Ser36 phos-
phorylation leads to decreased apoptosis since phosphoryl-
ation of Ser36 of p66Shc serves as a sensor of apoptotic
pathway [7]. The elevated level of p66Shc hence, plays a
critical role in up-regulating androgen-regulated prostate
cancer cell proliferation and contributes to the tumorigen-
icity of these cells. Furthermore, LNCaP C-81 and PC-3
prostate cancer cells which have high levels of p66Shc, ex-
hibit higher metastatic potential than LNCaP C-33 cells
[101]. In androgen stimulated prostate cancer cells elevated
p66Shc expression correlated with increased ROS levels
and increased cell proliferation. This increase in cell prolif-
eration was blocked by treating with antioxidants as well as
by the knockout of p66Shc. Androgens lead to the in-
creased expression of p66Shc, which in turn leads to an in-
creased production of ROS [102].
p66Shc in esophageal cancer
A consistent increase in the p66Shc protein levels were
observed in ESCC (esophageal squamous cell carcinoma)
and EAC (esophageal adenocarcinoma). The controls of
ESCC showed a lower basal level of p66Shc expression
[75]. In the same study a 4–8 fold increase in the level of
expression of p66Shc was observed in ESCC and a 2–3 fold
increase was seen in EAC by densitometric analysis. The
pronounced activity of various gastric juices, bile acids and
digestive enzymes in lower gastrointestinal tract may be re-
sponsible for the higher levels of ROS in esophageal adeno-
carcinoma [103], which can be a reason for the higher basal
expression level of p66Shc in EAC as compared to the
lower levels in ESCC [75]. The levels of downstream targets
of p66Shc were also checked and higher levels of EpS8 and
Rac1 were observed in ESCC, as well as, EAC as compared
to adjacent normal tissue [75]. p66Shc promotes a trimetric
complex formation between EpS8, E3b1 and Sos1, which in
turn leads to increased Rac1 activity [31] (Figure 4).p66Shc in thyroid cancer
The expression of p66Shc was seen to be increased in all
kinds of proliferating thyroid tissues, but not in the nor-
mal thyroid tissue of the same patient [104]. This data
makes sense in the view of the fact that rapid growing
cells have activated metabolic reactions and those lead
to increased ROS production [105]. p66Shc is involved
in the oxidative stress signaling cascade which leads to
the production of H2O2 [6], through the p66Shc-Rac1
pathway [47].
p66Shc in lung cancer
Aiolos, which is often expressed in lung cancers and cor-
related with reduced patient survival, has been seen to
be inversely correlated with the expression of p66Shc in
lung cancer tissue as well as in single cells [106]. On the
other hand, Shc has been known to amplify the mito-
genic signal delivered by the hepatocyte growth factor
receptor Met in BN-14 mouse bile duct as well as A549
lung carcinoma cells [30]. p66Shc deficiency in human
lung adenocarcinoma A549 cells was seen to mitigate
the low nutrient induced autophagy. p66Shc inhibition
in these cells by shRNA also lead to prolonged phos-
phorylation of (ERK)1/2 kinase. Cleavage of caspase 7,
but not of caspase 6 and 9 was also observed under
these conditions in the A549 cells, pointing to the fact
that p66Shc may play a role in regulating autophagy and
apoptotic resistance under conditions of limited nutrients
[107]. In clinical human lung cancer samples and cancer
cell lines, methylation of a specific CpG site in the post-
transcriptional region was seen to be correlated with the
p66Shc repression. The association of stress related tran-
scription factor Nrf2 requires the demethylation of the
Nrf2 binding site in the promoter of p66Shc, in order for
Nrf2 to promote the transcription of p66Shc. Nrf2 upregu-
lation along with increased cell survival and tumor progres-
sion in these cancer cells might be as a result of the
epigenetic repression of p66Shc [108].
p66Shc in ovarian cancer
In ovarian cancer cells the level of ErbB-2 expression
positively correlates with the level of p66Shc. ErbB-2 is a
prognostic marker for ovarian carcinoma [34]. In ovarian
cancer tissues, cancerous cells show higher levels of p66Shc
proteins as compared to the adjacent non-cancerous cells
[109]. In steroid treated ovarian cancer cells, p66Shc levels
were up regulated, along with increased cell proliferation.
When treated with the respective antagonists, these effects
on p66Shc levels were competed out [50]. Treatment of
ovarian cancer cells with proteasomal inhibitors lead to
higher levels of p66Shc protein. Immunoprecipitation ex-
periments have shown that the elevation of p66Shc levels
by the treatment of steroids and proteasomal inhibitors was
a result of reduced ubiquitination of p66Shc protein in
Figure 4 Schematic representation of the role of EpS8, E3b1 and Rac1 in oxidative stress induced p66Shc mediated carcinogenesis.
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hibit the binding of mortalin (HSPA9) binding to p53 and
p66Shc in ovarian cancer cells [111]. SHetA2 has been
identified of having cancer prevention properties and hence
therapeutic activity. The role of p66Shc was studied with
respect to regulating cell proliferation in ovarian cancer. It
was observed that the slowest growing cell line, OVCAR-3,
showed the lowest level of p66Shc expression. In addition
to this, transient transfection with p66Shc cDNA expres-
sion vector in OVCAR-3 cell line resulted in an increase in
cell proliferation [109].Figure 5 p66Shc: A dual player – role of p66Shc in cell proliferation ap66Shc in colon cancer
In colon cancer tissues, cancerous cells show higher
levels of p66Shc proteins as compared to the adjacent
non-cancerous cells [96]. p66Shc expression in benign,
premalignant, and malignant gastric and colorectal le-
sions was investigated in a separate study. Normal colo-
rectal and gastric tissue samples showed low or no p66Shc
expression. As opposed to the normal tissue, the gastric
and colorectal tumors showed moderate to high p66Shc
expression [112]. It was also seen that colon carcinoma cell
line RKO was more resistant to oxidative stress induced bynd cell proliferation.
Bhat et al. Molecular Cancer  (2015) 14:76 Page 9 of 12hydrogen peroxide exposure or serum starvation when
p66Shc was knocked out. Mitochondrial fragmentation
was also reduced in these p66Shc deficient RKO cells.
Mitochondrial fragmentation is in turn proportional to
the amount of mitochondrial ROS, therefore, showing
the role of p66Shc in the mitochondrial accumulation
of ROS [113].
Conclusion and prospective
A recent study has shown the regulatory role of p66Shc-
derived mitochondrial ROS. The p66Shc-derived ROS
has a regulatory role on growth factor signaling by in-
duction of protein tyrosine phosphatase (PTP) oxidation.
It was seen that p66Shcdeletion and down regulation
lead to decrease in PDGF-induced signaling and migra-
tion, by decreasing PDGF-induced PTP oxidation [114].
In summation, all these observations clearly show the
role of p66Shc in cell proliferation and the presence of
increased p66Shc expression in different cancer cell
lines/tissues and its effects leading to higher metastatic
ability in these cell lines. In addition to its role in cell
proliferation, p66Shc is known for being an important
apoptosis regulator. These observations point towards a
dual, albeit paradoxical role of p66Shc. While p66Shc
acts as a proto-oncogene on one side, showing increased
p66Shc expression in different cancer cell lines/cancer
tissues, and leading to increased cell proliferation and
metastatic potential by targeting various signaling path-
ways. On the other hand it acts as a pro-apoptotic pro-
tein. Its absence in cells prevents or inhibits apoptosis
and in addition to that it has been found to be a down-
stream effector of p53. p53 is a well-known tumor sup-
pressor as well as a pro-apoptotic protein. In response
to oxidative stress, the level of p66Shc activation in-
creases and p66Shc−/− cells are unable to undergo apop-
tosis in response to oxidative stress. These properties of
p66Shc belong to two different ends of spectrum, where its
apparent role as a pro-apoptotic protein totally conflicts
with its role as a proto-oncogene. p66Shc is not a unique
protein falling in the category of dual regulators of cell
growth. It is possible that p66Shc through growth factor
stimulation/regulation may contribute to cell proliferation
while as its regulation through oxidative stress might pre-
dominantly contribute to apoptosis (Figure 5). Varying
levels of ROS may play a deciding role in contributing to
these contrasting responses in the cell, where the intracellu-
lar levels of ROS may predominantly determine the route a
cell will take. Since p66Shc is involved in the produc-
tion and control of ROS, therefore, ROS seems to be
an important factor in the cell vis-à-vis deciding the
different cell responses. Steady state level of ROS or
acute production of intracellular ROS may lead a cell
towards different paths and ultimately different fates.
The role of ROS levels in apoptosis is well established.A correlation between p66Shc expression, ROS levels
and growth stimulation has been observed in prostate
cancer cells where increased p66Shc levels as well as
increased ROS levels were observed in addition to in-
creased growth. This growth stimulation was abolished
when the cells were treated with antioxidants [101]. It
may be that, under normal ROS concentration, the cell
will function normally. A slight increase in ROS level
may lead to ROS acting as a secondary messenger at an
elevated rate leading to increased or excessive cell pro-
liferation. A higher outburst of ROS may contribute to
oxidation damaged DNA in a cell and in turn might trigger
the oxidation stress induced pathway via p66Shcthat leads
to apoptosis.
p66Shc being a candidate protein that controls both cell
death as well as cell proliferation and plays a crucial role in
regulating longevity and cell senescence, by regulating
intracellular ROS levels. These counteracting properties of
p66Shc make it a perfect candidate for further studies in
various cancers and aging related diseases. p66Shc can be
targeted in terms of it being used as a possible therapeutic
target in various diseases, by figuring out how to use
p66Shc protein for balancing the ROS levels in the cells
and tipping the scales in our favor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SSB collected most of the literature and prepared the rough draft of the
review. DA, Helped in collecting some literature and revision of the MS. FAK,
overall invigilator on the study, edited and prepared the final draft of the
review. All authors read and approved the final manuscript.
Acknowledgments
This work was supported by the University Grants Commission No F. 17-82/
2008(SA-I) awarded to SS Bhat. Work was also partly supported by Deanship of
Research, King Fahad University of Petroleum and Minerals, Dhahran, KSA.
Author details
1Department Of Biotechnology, University of Kashmir, Srinagar 190006,
Kashmir, India. 2Department of Life Sciences, King Fahad University of
Petroleum and Minerals, Bld: 7, Room: 129, Dhahran 31261, Kingdom of
Saudi Arabia.
Received: 24 December 2014 Accepted: 29 March 2015
References
1. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, et al.
Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in
activation of the Ras pathway by tyrosine kinases. Nature. 1992;360:689–92.
2. Nakamura T, Muraoka S, Sanokawa R, Mori N. N-Shc and Sck, two neuronally
expressed Shc adapter homologs. Their differential regional expression in the
brain and roles in neurotrophin and Src signaling. J Biol Chem. 1998;273:6960–7.
3. Bonfini L, Migliaccio E, Pelicci G, Lanfrancone L, Pelicci PG. Not all Shc’s
roads lead to Ras. Trends Biochem Sci. 1996;21:257–61.
4. Ravichandran KS. Signaling via Shc family adapter proteins. Oncogene.
2001;20:6322–30.
5. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, et al. A
novel transforming protein (SHC) with an SH2 domain is implicated in
mitogenic signal transduction. Cell. 1992;70:93–104.
Bhat et al. Molecular Cancer  (2015) 14:76 Page 10 of 126. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, et al. The
p66shc adaptor protein controls oxidative stress response and life span in
mammals. Nature. 1999;402:309–13.
7. Ventura A, Luzi L, Pacini S, Baldari CT, Pelicci PG. The p66Shc longevity gene
is silenced through epigenetic modifications of an alternative promoter. J
Biol Chem. 2002;277:22370–6.
8. Luzi L, Confalonieri S, Di Fiore PP, Pelicci PG. Evolution of Shc functions
from nematode to human. Curr Opin Genet Dev. 2000;10:668–74.
9. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D. The SH2 and
SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras
activator mSos1. Nature. 1993;363:83–5.
10. Pelicci G, Dente L, De Giuseppe A, Verducci-Galletti B, Giuli S, Mele S, et al. A
family of Shc related proteins with conserved PTB, CH1 and SH2 regions.
Oncogene. 1996;13:633–41.
11. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, et al.
Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on
the EGF receptor-MAP kinase-fos signalling pathway. EMBO J. 1997;16:706–16.
12. Pacini S, Pellegrini M, Migliaccio E, Patrussi L, Ulivieri C, Ventura A, et al.
p66SHC promotes apoptosis and antagonizes mitogenic signaling in T cells.
Mol Cell Biol. 2004;24:1747–57.
13. Okada S, Kao AW, Ceresa BP, Blaikie P, Margolis B, Pessin JE. The 66-kDa Shc
isoform is a negative regulator of the epidermal growth factor-stimulated
mitogen-activated protein kinase pathway. J Biol Chem. 1997;272:28042–9.
14. Nemoto S, Combs CA, French S, Ahn BH, Fergusson MM, Balaban RS, et al. The
mammalian longevity-associated gene product p66shc regulates mitochondrial
metabolism. J Biol Chem. 2006;281:10555–60.
15. Innocenti M, Tenca P, Frittoli E, Faretta M, Tocchetti A, Di Fiore PP, et al.
Mechanisms through which Sos-1 coordinates the activation of Ras and
Rac. J Cell Biol. 2002;156:125–36.
16. Khanday FA, Yamamori T, Mattagajasingh I, Zhang Z, Bugayenko A, Naqvi A,
et al. Rac1 leads to phosphorylation-dependent increase in stability of the
p66shc adaptor protein: role in Rac1-induced oxidative stress. Mol Biol Cell.
2006;17:122–9.
17. Arany I, Faisal A, Nagamine Y, Safirstein RL. p66shc inhibits pro-survival epidermal
growth factor receptor/ERK signaling during severe oxidative stress in mouse
renal proximal tubule cells. J Biol Chem. 2008;283:6110–7.
18. Lithgow GJ, Kirkwood TB. Mechanisms and evolution of aging. Science.
1996;273:80.
19. Orr WC, Sohal RS. Extension of life-span by overexpression of superoxide
dismutase and catalase in Drosophila melanogaster. Science.
1994;263:1128–30.
20. Stracke ML, Engel JD, Wilson LW, Rechler MM, Liotta LA, Schiffmann E. The
type I insulin-like growth factor receptor is a motility receptor in human
melanoma cells. J Biol Chem. 1989;264:21544–9.
21. Berniakovich I, Trinei M, Stendardo M, Migliaccio E, Minucci S, Bernardi P,
et al. p66Shc-generated oxidative signal promotes fat accumulation. J Biol
Chem. 2008;283:34283–93.
22. Soliman MA, Abdel Rahman AM, Lamming DW, Birsoy K, Pawling J, Frigolet
ME, et al. The adaptor protein p66Shc inhibits mTOR-dependent anabolic
metabolism. Sci Signal. 2014;7:ra17.
23. Kumar S, Vikram A, Kim YR, SJ J, Irani K. P66Shc mediates increased platelet
activation and aggregation in hypercholesterolemia. Biochem Biophys Res
Commun. 2014;449:496–501.
24. Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B,
et al. Oxidative stress-mediated cardiac cell death is a major determinant of
ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res.
2001;89:279–86.
25. De Marchi E, Baldassari F, Bononi A, Wieckowski MR, Pinton P. Oxidative
stress in cardiovascular diseases and obesity: role of p66Shc and protein
kinase C. Oxid Med Cell Longev. 2013;2013:564961.
26. Savino C, Pelicci P, Giorgio M. The P66Shc/mitochondrial permeability
transition pore pathway determines neurodegeneration. Oxid Med Cell
Longev. 2013;2013:719407.
27. Bashir M, Parray AA, Baba RA, Bhat HF, Bhat SS, Mushtaq U, et al. beta-
Amyloid-evoked apoptotic cell death is mediated through MKK6-p66shc
pathway. Neuromolecular Med. 2014;16:137–49.
28. Canevari L, Abramov AY, Duchen MR. Toxicity of amyloid beta peptide: tales of
calcium, mitochondria, and oxidative stress. Neurochem Res. 2004;29:637–50.
29. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, et al.
Electron transfer between cytochrome c and p66Shc generates reactive
oxygen species that trigger mitochondrial apoptosis. Cell. 2005;122:221–33.30. Pellegrini M, Pacini S, Baldari CT. p66SHC: the apoptotic side of Shc proteins.
Apoptosis. 2005;10:13–8.
31. Jackson JG, Yoneda T, Clark GM, Yee D. Elevated levels of p66 Shc are found
in breast cancer cell lines and primary tumors with high metastatic
potential. Clin Cancer Res. 2000;6:1135–9.
32. Stevenson LE, Frackelton Jr AR. Constitutively tyrosine phosphorylated p52
Shc in breast cancer cells: correlation with ErbB2 and p66 Shc expression.
Breast Cancer Res Treat. 1998;49:119–28.
33. Veeramani S, Igawa T, Yuan TC, Lin FF, Lee MS, Lin JS, et al. Expression of
p66(Shc) protein correlates with proliferation of human prostate cancer
cells. Oncogene. 2005;24:7203–12.
34. Xie Y, Hung MC. p66Shc isoform down-regulated and not required for HER-
2/neu signaling pathway in human breast cancer cell lines with HER-2/neu
overexpression. Biochem Biophys Res Commun. 1996;221:140–5.
35. Miyazawa M, Tsuji Y. Evidence for a novel antioxidant function and isoform-
specific regulation of the human p66Shc gene. Mol Biol Cell. 2014;25:2116–27.
36. Galimov ER, Chernyak BV, Sidorenko AS, Tereshkova AV, Chumakov PM.
Prooxidant properties of p66shc are mediated by mitochondria in human
cells. PLoS One. 2014;9:e86521.
37. Foschi M, Franchi F, Han J, La Villa G, Sorokin A. Endothelin-1 induces serine
phosphorylation of the adaptor protein p66Shc and its association with 14-3-3
protein in glomerular mesangial cells. J Biol Chem. 2001;276:26640–7.
38. Faisal A, el-Shemerly M, Hess D, Nagamine Y. Serine/threonine phosphorylation of
ShcA. Regulation of protein-tyrosine phosphatase-pest binding and involvement
in insulin signaling. J Biol Chem. 2002;277:30144–52.
39. Park YJ, Kim TY, Lee SH, Kim H, Kim SW, Shong M, et al. p66Shc expression
in proliferating thyroid cells is regulated by thyrotropin receptor signaling.
Endocrinology. 2005;146:2473–80.
40. Le S, Connors TJ, Maroney AC. c-Jun N-terminal kinase specifically phosphorylates
p66ShcA at serine 36 in response to ultraviolet irradiation. J Biol Chem.
2001;276:48332–6.
41. Yang CP, Horwitz SB. Distinct mechanisms of taxol-induced serine phosphorylation
of the 66-kDa Shc isoform in A549 and RAW 264.7 cells. Biochim Biophys Acta.
2002;1590:76–83.
42. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42
GTPases in cell cycle progression through G1. Science. 1995;269:1270–2.
43. Meng TC, Lee MS, Lin MF. Interaction between protein tyrosine
phosphatase and protein tyrosine kinase is involved in androgen-promoted
growth of human prostate cancer cells. Oncogene. 2000;19:2664–77.
44. Stevenson MA, Pollock SS, Coleman CN, Calderwood SK. X-irradiation, phorbol
esters, and H2O2 stimulate mitogen-activated protein kinase activity in NIH-3T3 cells
through the formation of reactive oxygen intermediates. Cancer Res. 1994;54:12–5.
45. Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, Piccini D, et al. The
life span determinant p66Shc localizes to mitochondria where it associates
with mitochondrial heat shock protein 70 and regulates trans-membrane
potential. J Biol Chem. 2004;279:25689–95.
46. Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, Migliaccio E, et al. A
p53-p66Shc signalling pathway controls intracellular redox status, levels of
oxidation-damaged DNA and oxidative stress-induced apoptosis. Oncogene.
2002;21:3872–8.
47. Khanday FA, Santhanam L, Kasuno K, Yamamori T, Naqvi A, Dericco J, et al.
Sos-mediated activation of rac1 by p66shc. J Cell Biol. 2006;172:817–22.
48. Xie ZZ, Shi MM, Xie L, Wu ZY, Li G, Hua F, et al. Sulfhydration of p66Shc at
Cysteine59 Mediates the Antioxidant Effect of Hydrogen Sulfide. Antioxid
Redox Signal. 2014;18:2531–42.
49. Vikram A, Kim YR, Kumar S, Naqvi A, Hoffman TA, Kumar A, et al. Canonical Wnt
signaling induces vascular endothelial dysfunction via p66Shc-regulated reactive
oxygen species. Arterioscler Thromb Vasc Biol. 2014;34:2301–9.
50. Alam SM, Rajendran M, Ouyang S, Veeramani S, Zhang L, Lin MF. A novel
role of Shc adaptor proteins in steroid hormone-regulated cancers. Endocr
Relat Cancer. 2009;16:1–16.
51. Pages G, Lenormand P, L’Allemain G, Chambard JC, Meloche S, Pouyssegur J.
Mitogen-activated protein kinases p42mapk and p44mapk are required for
fibroblast proliferation. Proc Natl Acad Sci U S A. 1993;90:8319–23.
52. Nemoto S, Finkel T. Redox regulation of forkhead proteins through a
p66shc-dependent signaling pathway. Science. 2002;295:2450–2.
53. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the
degenerative diseases of aging. Proc Natl Acad Sci U S A. 1993;90:7915–22.
54. Favetta LA, Robert C, King WA, Betts DH. Expression profiles of p53 and p66shc
during oxidative stress-induced senescence in fetal bovine fibroblasts. Exp Cell
Res. 2004;299:36–48.
Bhat et al. Molecular Cancer  (2015) 14:76 Page 11 of 1255. Jiang X, Edstrom E, Altun M, Ulfhake B. Differential regulation of Shc
adaptor proteins in skeletal muscle, spinal cord and forebrain of aged rats
with sensorimotor impairment. Aging Cell. 2003;2:47–57.
56. Klein LE, Freeze BS, Smith 3rd AB, Horwitz SB. The microtubule stabilizing
agent discodermolide is a potent inducer of accelerated cell senescence.
Cell Cycle. 2005;4:501–7.
57. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol.
2003;552:335–44.
58. Migliaccio E, Giorgio M, Pelicci PG. Apoptosis and aging: role of p66Shc redox
protein. Antioxid Redox Signal. 2006;8:600–8.
59. Helbock HJ, Beckman KB, Ames BN. 8-Hydroxydeoxyguanosine and 8-
hydroxyguanine as biomarkers of oxidative DNA damage. Methods
Enzymol. 1999;300:156–66.
60. Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, et al.
Signaling through ShcA is required for transforming growth factor beta- and
Neu/ErbB-2-induced breast cancer cell motility and invasion. Mol Cell Biol.
2008;28:3162–76.
61. Ratner S, Patrick P, Bora G. Lymphocyte development of adherence and motility
in extracellular matrix during IL-2 stimulation. J Immunol. 1992;149:681–8.
62. Giorgio M, Berry A, Berniakovich I, Poletaeva I, Trinei M, Stendardo M, et al. The
p66Shc knocked out mice are short lived under natural condition. Aging Cell.
2012;11:162–8.
63. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces
apoptosis. J Cell Biol. 1994;124:619–26.
64. Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in
cancer progression. Biochim Biophys Acta. 1833;2013:3481–98.
65. Ma Z, Myers DP, Wu RF, Nwariaku FE, Terada LS. p66Shc mediates anoikis
through RhoA. J Cell Biol. 2007;179:23–31.
66. Ma Z, Liu Z, Wu RF, Terada LS. p66(Shc) restrains Ras hyperactivation and
suppresses metastatic behavior. Oncogene. 2010;29:5559–67.
67. Pinton P, Rizzuto R. p66Shc, oxidative stress and aging: importing a lifespan
determinant into mitochondria. Cell Cycle. 2008;7:304–8.
68. Anand-Apte B, Zetter BR, Viswanathan A, Qiu RG, Chen J, Ruggieri R, et al.
Platelet-derived growth factor and fibronectin-stimulated migration are
differentially regulated by the Rac and extracellular signal-regulated kinase
pathways. J Biol Chem. 1997;272:30688–92.
69. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA.
Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol.
1997;137:481–92.
70. Sastre J, Pallardo FV, Vina J. The role of mitochondrial oxidative stress in
aging. Free Radic Biol Med. 2003;35:1–8.
71. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated
molecular process. Cell. 1996;84:359–69.
72. Klemke RL, Yebra M, Bayna EM, Cheresh DA. Receptor tyrosine kinase
signaling required for integrin alpha v beta 5-directed cell motility but not
adhesion on vitronectin. J Cell Biol. 1994;127:859–66.
73. Huttenlocher A, Sandborg RR, Horwitz AF. Adhesion in cell migration. Curr
Opin Cell Biol. 1995;7:697–706.
74. Guo M, Hay BA. Cell proliferation and apoptosis. Curr Opin Cell Biol.
1999;11:745–52.
75. Bashir M, Kirmani D, Bhat HF, Baba RA, Hamza R, Naqash S, et al. P66shc and
its downstream Eps8 and Rac1 proteins are upregulated in esophageal
cancers. Cell Commun Signal. 2010;8:13.
76. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer.
Nature. 2001;411:342–8.
77. Ginaldi L, De Martinis M, D’Ostilio A, Marini L, Loreto MF, Corsi MP, et al. Cell
proliferation and apoptosis in the immune system in the elderly. Immunol
Res. 2000;21:31–8.
78. Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor released by
single, isolated cells stimulates their migration in an autocrine manner. Proc
Natl Acad Sci U S A. 1991;88:11007–11.
79. Lee MS, Igawa T, Chen SJ, Van Bemmel D, Lin JS, Lin FF, et al. p66Shc
protein is upregulated by steroid hormones in hormone-sensitive cancer
cells and in primary prostate carcinomas. Int J Cancer. 2004;108:672–8.
80. Sachs M, Weidner KM, Brinkmann V, Walther I, Obermeier A, Ullrich A, et al.
Motogenic and morphogenic activity of epithelial receptor tyrosine kinases.
J Cell Biol. 1996;133:1095–107.
81. Chobanyan NS. Re: Henderson,B.E. and Feigelson,H.S. (2000) hormonal
carcinogenesis. Carcinogenesis, 21, 427–433. Carcinogenesis. 2001;22:529.
82. Dabrosin C, Ollinger K, Ungerstedt U, Hammar M. Variability of glutathione
levels in normal breast tissue and subcutaneous fat during the menstrualcycle: an in vivo study with microdialysis technique. J Clin Endocrinol
Metab. 1997;82:1382–4.
83. Devanesan P, Santen RJ, Bocchinfuso WP, Korach KS, Rogan EG, Cavalieri E.
Catechol estrogen metabolites and conjugates in mammary tumors and
hyperplastic tissue from estrogen receptor-alpha knock-out (ERKO)/Wnt-1
mice: implications for initiation of mammary tumors. Carcinogenesis.
2001;22:1573–6.
84. Dickson RB, Lippman ME. Estrogenic regulation of growth and polypeptide
growth factor secretion in human breast carcinoma. Endocr Rev. 1987;8:29–43.
85. Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression.
Physiology (Bethesda). 2010;25:85–101.
86. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in
androgen-refractory prostate cancer. J Natl Cancer Inst. 2001;93:1687–97.
87. Weigel NL, Moore NL. Kinases and protein phosphorylation as regulators of
steroid hormone action. Nucl Recept Signal. 2007;5:e005.
88. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, et al. Regulation of androgen
receptor activity by tyrosine phosphorylation. Cancer Cell. 2006;10:309–19.
89. Kraus S, Gioeli D, Vomastek T, Gordon V, Weber MJ. Receptor for activated C
kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and
function of the androgen receptor. Cancer Res. 2006;66:11047–54.
90. Hamada J, Nagayasu H, Takayama M, Kawano T, Hosokawa M, Takeichi N.
Enhanced effect of epidermal growth factor on pulmonary metastasis
and in vitro invasion of rat mammary carcinoma cells. Cancer Lett.
1995;89:161–7.
91. Engebraaten O, Bjerkvig R, Pedersen PH, Laerum OD. Effects of EGF, bFGF,
NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of
human brain-tumour biopsies in vitro. Int J Cancer. 1993;53:209–14.
92. Natalicchio A, Laviola L, De Tullio C, Renna LA, Montrone C, Perrini S, et al.
Role of the p66Shc isoform in insulin-like growth factor I receptor signaling
through MEK/Erk and regulation of actin cytoskeleton in rat myoblasts. J
Biol Chem. 2004;279:43900–9.
93. Choudhury GG, Karamitsos C, Hernandez J, Gentilini A, Bardgette J,
Abboud HE. PI-3-kinase and MAPK regulate mesangial cell proliferation
and migration in response to PDGF. Am J Physiol. 1997;273:F931–8.
94. Taub J, Lau JF, Ma C, Hahn JH, Hoque R, Rothblatt J, et al. A cytosolic
catalase is needed to extend adult lifespan in C. elegans daf-C and clk-1
mutants. Nature. 1999;399:162–6.
95. Taylor WR, Greenberg AH, Turley EA, Wright JA. Cell motility, invasion, and
malignancy induced by overexpression of K-FGF or bFGF. Exp Cell Res.
1993;204:295–301.
96. Grossman SR, Lyle S, Resnick MB, Sabo E, Lis RT, Rosinha E, et al. p66 Shc
tumor levels show a strong prognostic correlation with disease outcome in
stage IIA colon cancer. Clin Cancer Res. 2007;13:5798–804.
97. Davol PA, Bagdasaryan R, Elfenbein GJ, Maizel AL, Frackelton Jr AR. Shc
proteins are strong, independent prognostic markers for both node-
negative and node-positive primary breast cancer. Cancer Res.
2003;63:6772–83.
98. De S, Razorenova O, McCabe NP, O’Toole T, Qin J, Byzova TV. VEGF-
integrin interplay controls tumor growth and vascularization. Proc Natl
Acad Sci U S A. 2005;102:7589–94.
99. Haines E, Saucier C, Claing A. The adaptor proteins p66Shc and Grb2
regulate the activation of the GTPases ARF1 and ARF6 in invasive breast
cancer cells. J Biol Chem. 2014;289:5687–703.
100. Bhat HF, Baba RA, Adams ME, Khanday FA. Role of SNTA1 in Rac1 activation,
modulation of ROS generation, and migratory potential of human breast
cancer cells. Br J Cancer. 2014;110:706–14.
101. Veeramani S, Yuan TC, Lin FF, Lin MF. Mitochondrial redox signaling by
p66Shc is involved in regulating androgenic growth stimulation of human
prostate cancer cells. Oncogene. 2008;27:5057–68.
102. Veeramani S, Chou YW, Lin FC, Muniyan S, Lin FF, Kumar S, et al. Reactive
oxygen species induced by p66Shc longevity protein mediate nongenomic
androgen action via tyrosine phosphorylation signaling to enhance
tumorigenicity of prostate cancer cells. Free Radic Biol Med. 2012;53:95–108.
103. Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives
on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis.
2001;22:1119–29.
104. Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, et al. The
motogenic and mitogenic responses to HGF are amplified by the Shc
adaptor protein. Oncogene. 1995;10:1631–8.
105. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int
J Cancer. 1999;81:682–7.
Bhat et al. Molecular Cancer  (2015) 14:76 Page 12 of 12106. Li X, Xu Z, Du W, Zhang Z, Wei Y, Wang H, et al. Aiolos promotes
anchorage independence by silencing p66Shc transcription in cancer cells.
Cancer Cell. 2014;25:575–89.
107. Zheng Z, Yang J, Zhao D, Gao D, Yan X, Yao Z, et al. Downregulated
adaptor protein p66(Shc) mitigates autophagy process by low nutrient and
enhances apoptotic resistance in human lung adenocarcinoma A549 cells.
FEBS J. 2013;280:4522–30.
108. Du W, Jiang Y, Zheng Z, Zhang Z, Chen N, Ma Z, et al. Feedback loop
between p66(Shc) and Nrf2 promotes lung cancer progression. Cancer Lett.
2013;337:58–65.
109. Muniyan S, Chou YW, Tsai TJ, Thomes P, Veeramani S, Benigno BB, et al.
p66Shc longevity protein regulates the proliferation of human ovarian
cancer cells. Mol Carcinog. 2014. [Epub ahead of print]
110. Kumar S, Kumar S, Rajendran M, Alam SM, Lin FF, Cheng PW, et al. Steroids
up-regulate p66Shc longevity protein in growth regulation by inhibiting its
ubiquitination. PLoS One. 2011;6:e15942.
111. Benbrook DM, Nammalwar B, Long A, Matsumoto H, Singh A, Bunce RA,
et al. SHetA2 interference with mortalin binding to p66shc and p53
identified using drug-conjugated magnetic microspheres. Invest New Drugs.
2014;32:412–23.
112. Liu G, Xie B, Gong L, Zhou J, Shu G. The expression of p66Shc protein in
benign, premalignant, and malignant gastrointestinal lesions. Pathol Oncol
Res. 2014;20:733–9.
113. Galimov ER, Sidorenko AS, Tereshkova AV, Pletiushkina O, Cherniak BV,
Chumakov PM. P66shc action on resistance of colon carcinoma RKO cells to
oxidative stress. Mol Biol (Mosk). 2012;46:139–46.
114. Frijhoff J, Dagnell M, Augsten M, Beltrami E, Giorgio M, Ostman A. The
mitochondrial reactive oxygen species regulator p66Shc controls PDGF-induced
signaling and migration through protein tyrosine phosphatase oxidation. Free
Radic Biol Med. 2014;68:268–77.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
